NS1619, a BK channel activator, protected the cells expressing G354S BK from the reduced neurite outgrowth, cell death, and changes in mitochondria, suggesting that the recovery of BK channel function can be a therapy for the neurological diseases associated with BK channel LOF mutations. This evidence concerns the gene KNG1 and nervous system disorder.